In animal models of NASH, treatment with NGM282 resulted in rapid and profound reductions in the concentrations of ALT and AST, as well as clear improvements in all histological features of NASH with suppression of de novo bile acid synthesis and inhibition of fatty acid synthesis and de novo lipogenesis, presumably through mechanisms that ameliorate hepatic bile acid toxicity and lipotoxicity [117]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.